4.6 Review

Myocardial fibrosis in rheumatic heart disease: emerging concepts and clinical implications

Journal

FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2023.1230894

Keywords

myocardial fibrosis; rheumatic heart disease; Group A Streptoccocus; cross reactivity; LV dysfunction

Ask authors/readers for more resources

Rheumatic heart disease (RHD) is still a significant global cardiovascular burden, although it is no longer common in wealthy countries. Centuries of history have given us a thorough understanding of RHD's pathophysiology. Infections caused by Group A Streptococcus (GAS) trigger an immune response that leads to inflammation and cardiac dysfunction. Myocardial fibrosis, which is prevalent in RHD patients, can be used to determine treatment options and predict intervention outcomes.
Rheumatic heart disease (RHD) remains a significant cardiovascular burden in the world even though it is no longer common in affluent countries. Centuries of history surrounding this disease provide us with a thorough understanding of its pathophysiology. Infections in the throat, skin, or mucosa are the gateway for Group A Streptococcus (GAS) to penetrate our immune system. A significant inflammatory response to the heart is caused by an immunologic cascade triggered by GAS antigen cross-reactivity. This exaggerated immune response is primarily responsible for cardiac dysfunction. Recurrent inflammatory processes damage all layers of the heart, including the endocardium, myocardium, and pericardium. A vicious immunological cycle involving inflammatory mediators, angiotensin II, and TGF-& beta; promotes extracellular matrix remodeling, resulting in myocardial fibrosis. Myocardial fibrosis appears to be a prevalent occurrence in patients with RHD. The presence of myocardial fibrosis, which causes left ventricular dysfunction in RHD, might be utilized to determine options for treatment and might also be used to predict the outcome of interventions in patients with RHD. This emerging concept of myocardial fibrosis needs to be explored comprehensively in order to be optimally utilized in the treatment of RHD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available